Advertisement

Neuroscience and Behavioral Physiology

, Volume 42, Issue 8, pp 842–845 | Cite as

Antioxidant Treatment of Ischemic Brain Lesions

  • S. A. Rumyantseva
  • A. I. Fedin
  • O. N. Sokhova
Article

Keywords

antioxidant treatment Mexidol stroke 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    V. S. Vilenskii and I. I. Anosov, Stroke [in Russian], Meditsina, Leningrad (1980).Google Scholar
  2. 2.
    E. I. Gusev,V. I. Skvortsova, and L. V. Stakhovskaya, “Epidemiology of stroke in Russia,” Zh. Nevrol. Psikhiat., 9, Stroke Suppl., 114 (2003).Google Scholar
  3. 3.
    E. I. Gusev, “The problem of stroke in Russia,” Zh. Nevrol. Psikhiat., 9, Stroke Suppl., 3–5 (2003).Google Scholar
  4. 4.
    V. I. Gusev and V. I. Skvortsova, Cerebral Ischemia [in Russian], Meditsina, Moscow (2001).Google Scholar
  5. 5.
    S. G. Burchinskii, “Current approaches to neuroprotection,” Novosti Med. Farm., No. 10–11, 6–7 (2004).Google Scholar
  6. 6.
    S. G. Burchinskii, “Neuroprotective pharmacology in geriatrics: protection of what for what,” Zdorovya Ukraini, 8, 42–43 (2006).Google Scholar
  7. 7.
    E. V. Verizhnikova, I. S. Petrusenko, and I. I. Sholomov, “Current aspects of cytoprotective correction and neuroresuscitation. Clinical pharmacology,” Byull. Eksperim. Biol. Med., No. 1, 14–17 (2005).Google Scholar
  8. 8.
    S. A. Rumyantseva,V. A. Stupin,V. V. Afanasiev, et al., Critical States in Clinical Practice [in Russian], Medical Books Int. Publ. Group (Meditsinskaya Kniga) (2011).Google Scholar
  9. 9.
    V. I. Skvortsova, “Treatment of acute ischemic stroke,” Neotlozh. Terapiya, No. 1–2, 20–24 (2005).Google Scholar
  10. 10.
    S. M. Vinichuk, “Oxidative stress in acute ischemic stroke and its correction with the antioxidant Mexidol,” Mezhdunarod. Nevrol. Zh., 4, 45–52 106Google Scholar
  11. 11.
    V. M. Vinogradov and B. I. Krivoruchko, “Pharmacological protection of the brain from hypoxia,” Psikhofarmakol. Biol. Narkol., No. 1, 27–37 (2001).Google Scholar
  12. 12.
    T. A. Voronina, Mexidol: Main Effects, Mechanism of Action, Use. Guidelines [in Russian] (2000).Google Scholar
  13. 13.
    T. A. Voronina, “The antioxidant Mexidol. Main neuropsychotropic effects and mechanisms of action,” Psikhofarmakol. Biol. Narkol., No. 1, 2–12 (2001).Google Scholar
  14. 14.
    T. A. Voronina, Mexidol: Main Effects, Mechanism of Action, Use [in Russian], Kazan (2004).Google Scholar
  15. 15.
    K. M. Dyumaev, T. A. Voronina, and L. D. Smirnov, Antioxidants in the Prophylaxis and Treatment of CNS Pathologies [in Russian], Moscow (1995).Google Scholar
  16. 16.
    M. A. Lutskii, “Oxidative stress and treatment with antioxidants,” Nerv. Bolezn., No. 3, 15–20 (2007).Google Scholar
  17. 17.
    V. I. Skvortsova, L. V. Stakhovskaya,Ya. R. Nartsissov, et al., “A randomized double-blind, placebo-controlled study of the efficacy and safety of Mexidol in the complex treatment of ischemic stroke in the acute period,” Zh. Nevrol. Psikhiat., 9, Stroke Suppl., 18 (2006).Google Scholar
  18. 18.
    Z. A. Suslina, T. N. Fedorova, M. Yu. Maksimova, et al., “Antioxidant treatment in ischemic stroke,” Zh. Nevrol. Psikhiat., No. 10, 34–38 (2000).Google Scholar
  19. 19.
    A. I. Fedin, S. A. Rumyantseva, O. P. Mironova, and V. N. Evseev, The Use of the Antioxidant Mexidol in Patients with Acute Cerebral Circulatory Lesions. Guidelines [in Russian], (2000).Google Scholar
  20. 20.
    D. V. Sadchikov, T. N. Kulikova, I. V. Lopatin, et al., Mexidol in the Treatment of Critical States [in Russian], Saratov (2005).Google Scholar
  21. 21.
    A. L. Shevchenko, “On the question of the therapeutic activity of Mexidol in the treatment of patients with ischemic strokes,” Mezhdunar. Nevrol. Zh., No. 6, 87–93 (2006).Google Scholar
  22. 22.
    T. A. Puzyreva, “The use of Mexidol in acute and chronic cerebrovascular diseases,” Nevrol. Psikhiat., No. 2, 27–30 (2004).Google Scholar
  23. 23.
    D. V. Sadchikov, T. N. Kulikova, I. V. Lopatin, and A. D. Zhiltsov, The Use of Mexidol in Critical States. Guidelines [in Russian], Moscow (2002).Google Scholar
  24. 24.
    G. I. Klebanov, O. B. Lyubitskii, O. V. Vasilieva, et al., “The antioxidant properties of 3-hydroxypyridine: Mexidol, emoxypine, and Proxipine,” Vopr. Med. Khimii, No. 3, 45–51 (2001).Google Scholar
  25. 25.
    S. M. Kuznetsova, “Mexidol in the rehabilitation of elderly patients with stroke,” Ukr. Nevrol. Zh., No. 3, 77–81 (2007).Google Scholar
  26. 26.
    V. E. Novikov, L. A. Kovaleva, S. O. Losenkova, et al., “The pharmacology of antioxidants based on hydroxypyridine,” Vestn. Smolenskoi Med. Akad., No. 1, 23–42 (2004).Google Scholar
  27. 27.
    I. S. Pavlov and L. A. Medvedeva, Mexidol in the Clinical Practice of Borderline Psychiatry [in Russian], Kazan, (2004).Google Scholar
  28. 28.
    N. V. Mironov, V. V. Sudneva, and I. I. Goryainova, “The use of Mexidol in the complex treatment of patients with ischemic stroke during the recovery period,” Kremlev. Med., No. 2, 27–29 (2001).Google Scholar
  29. 29.
    T. V. Ostrovaya, V. I. Chernii, G. A. Gorodnik, et al., “A trial of the effects of Mexidol on the functional state of the CNS in patients with ischemic stroke,” Mezhdunarod. Nevrol. Zh., No. 4, 51–56 (2005).Google Scholar
  30. 30.
    L. A. Medvedeva, “The use of Mexidol in the treatment of dyscirculatory encephalopathies,” Nevrol. Psikhiat., No. 4, 38–41 (2002).Google Scholar
  31. 31.
    D. V. Kandyba, N. M. Zhulev, G. Yu. Sokurenko, and O. S. Markova, “The use of Mexidol in the complex conservative and angiocorrective treatment of ischemic cerebral circulatory impairments of extracranial origin,” Zh. Farmateka, No. 7, 25–30, (2006).Google Scholar
  32. 32.
    S. Z. Umarov, “Pharmacoeconomic analysis of the medication therapy of cerebral circulatory impairments,” Zh. Farmateka, No. 5, 67–70 (2006).Google Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • S. A. Rumyantseva
    • 1
  • A. I. Fedin
    • 1
  • O. N. Sokhova
    • 1
  1. 1.Russian State Medical InstituteMoscowRussia

Personalised recommendations